Production, purificationand biological characterization of mono-PEGylated anti-IL-17A antibody fragments

International Journal of Pharmaceutics

Volumn 454, Issue 1, 2013, Pages 107-115

  Koussoroplis, Salome Juliette ^a   Heywood, Sam ^b   Uyttenhove, Catherine ^c,d   Barilly, Céline ^a   Van Snick, Jacques ^c,d   Vanbever, Rita ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UCB PHARMA   (Belgium)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^d DE DUVE INSTITUTE   (Belgium)

Author keywords

Anti interleukin 17A; Antibody fragment; Bronchial hyperreactivity; PEGylation

Indexed keywords

DRUG ANTIBODY; INTERLEUKIN 17A ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY FRAGMENT; GRANULOCYTE COLONY STIMULATING FACTOR; IL17A PROTEIN, MOUSE; IMMUNOGLOBULIN FRAGMENT; INTERLEUKIN 17; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROGOL; MACROGOL DERIVATIVE; N-HYDROXYSUCCINIMIDE; PHOSPHATE BUFFERED SALINE; POLYVINYLIDENE FLUORIDE;

ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BRONCHUS HYPERREACTIVITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG PURIFICATION; DRUG STABILITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; 2-MEA; 2-MERCAPTOETHYLAMINE·HCL; ANIMAL; ANTI-INTERLEUKIN-17A; ANTIBODY SPECIFICITY; AREA UNDER THE CURVE; BHR; BINDING COMPETITION; BIOSYNTHESIS; CEC; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; FAST PROTEIN LIQUID CHROMATOGRAPHY; FCS; FETAL CALF SERUM; FIBROBLAST; GBS; GCSF; GEL FILTRATION CHROMATOGRAPHY; GFC; GLYCINE BUFFERED SALINE; HSFM; HYBRIDOMA; HYBRIDOMA SERUM FREE MEDIUM; IMMUNOLOGY; ION EXCHANGE CHROMATOGRAPHY; ISOLATION AND PURIFICATION; MABS; METABOLISM; METHODOLOGY; MONOCLONAL ANTIBODIES; MOUSE; NHS; PBS; PEG; PEGYLATION; PHARMACEUTICS; PROTEIN STABILITY; VACCINATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; PROCEDURES;

2-MEA; 2-MERCAPTOETHYLAMINE·HCL; ANTI-INTERLEUKIN-17A; ANTIBODY FRAGMENT; AREA UNDER THE CURVE; AUC; BHR; BRONCHIAL HYPERREACTIVITY; CATION EXCHANGE CHROMATOGRAPHY; CEC; FAST PROTEIN LIQUID CHROMATOGRAPHY; FCS; FETAL CALF SERUM; FPLC; GBS; GCSF; GEL FILTRATION CHROMATOGRAPHY; GFC; GLYCINE BUFFERED SALINE; GRANULOCYTE COLONY-STIMULATING FACTOR; HSFM; HYBRIDOMA SERUM FREE MEDIUM; LIPOPOLYSACCHARIDE; LPS; MABS; MONOCLONAL ANTIBODIES; N-HYDROXYSUCCINIMIDE; NHS; PBS; PEG; PEGYLATION; PHOSPHATE BUFFERED SALINE; POLYETHYLENE GLYCOL; POLYVINYLIDENE FLUORIDE; PVDF;

ANIMALS; ANTIBODY SPECIFICITY; BINDING, COMPETITIVE; CELL LINE; FIBROBLASTS; HYBRIDOMAS; IMMUNOGLOBULIN FRAGMENTS; INTERLEUKIN-17; INTERLEUKIN-6; MICE; MOLECULAR STRUCTURE; POLYETHYLENE GLYCOLS; PROTEIN STABILITY; TECHNOLOGY, PHARMACEUTICAL; VACCINATION;

EID: 84884167628     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.06.077     Document Type: Article

References (36)

1. Andrew, S.M., Titus, J.A., 1997. Pilot fragmentation of IgG to F (ab′) 2 using pepsin. Curr. Protoc. Immunol., 2-8.
2. Bailon, P., Won, C.Y., 2009. PEG-modified biopharmaceuticals. Expert Opin. Drug Deliv. 6, 1-16.
3. Barczyk, A., Pierzchala, W., Sozańska, E., 2003. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir. Med. 97, 726-733. (Pubitemid 36675678)
4. Basu, A., Yang, K., Wang, M., Liu, S., Chintala, R., Palm, T., Zhao, H., Peng, P., Wu, D., Zhang, Z., 2006. Structure-function engineering of interferon-β-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjugate Chem. 17, 618-630. (Pubitemid 43794371)
5. Caliceti, P., Veronese, F.M., 2003. Pharmacokinetic and biodistribution properties of poly (ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 55, 1261-1277. (Pubitemid 37464561)
6. Casey, J.L., Napier, M.P., King, D.J., Pedley, R.B., Chaplin, L.C., Weir, N., Skelton, L., Green, A.J., Hope-Stone, L.D., Yarranton, G.T., 2002. Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study. Br. J. Cancer 86, 1401-1410. (Pubitemid 34548060)
7. Chan, A.C., Carter, P.J., 2010. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10, 301-316.
8. Chapman, A.P., 2002. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev. 54, 531-545. (Pubitemid 34615547)
9. Chapman, A.P., Antoniw, P., Spitali, M., West, S., Stephens, S., King, D.J., 1999. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol. 17, 780-783. (Pubitemid 29365106)
10. Fee, C.J., Van Alstine, J.M., 2006. PEG-proteins: reaction engineering and separation issues. Chem. Eng. Sci. 61, 924-939.
11. Griffiths, G.L., Chang, C.H., McBride, W.J., Rossi, E.A., Sheerin, A., Tejada, G.R., Karacay, H., Sharkey, R.M., Horak, I.D., Hansen, H.J., 2004. Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. J. Nucl. Med. 45, 30-39. (Pubitemid 47611605)
12. Holliger, P., Hudson, P.J., 2005. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23, 1126-1136. (Pubitemid 41486394)
13. Jorgensen, K.E., Moller, J.V., 1979. Use of flexible polymers as probes of glomerular pore size. Am. J. Physiol. - Renal Physiol. 236, F103-F111. (Pubitemid 9166413)
14. King, D.J., Turner, A., Farnsworth, A.P.H., Adair, J.R., Owens, R.J., Pedley, R.B., Baldock, D., Proudfoot, K.A., Lawson, A.D.G., Beeley, N.R.A., 1994. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res. 54, 6176-6185. (Pubitemid 24378651)
15. Knight, D.M., Jordan, R.E., Kruszynski, M., Tam, S.H., Giles-Komar, J., Treacy, G., Heavner, G.A., 2004. Pharmacodynamic enhancement of the anti-platelet antibody Fab abciximab by site-specific pegylation. Platelets 15, 409-418. (Pubitemid 39518182)
16. Kontermann, R.E., 2009. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 23, 93-109.
17. Koumenis, I.L., Shahrokh, Z., Leong, S., Hsei, V., Deforge, L., Zapata, G., 2000. Modulating pharmacokinetics of an anti-interleukin-8 F (ab′) 2 by amine-specific PEGylation with preserved bioactivity. Int. J. Pharm. 198, 83-95. (Pubitemid 30155552)
18. Kurfürst, M.M., 1992. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfatepolyacrylamide gel electrophoresis. Anal. Biochem. 200, 244-248.
19. Leong, S.R., DeForge, L., Presta, L., Gonzalez, T., Fan, A., Reichert, M., Chuntharapai, A., Jin Kim, K., Tumas, D.B., Lee, W.P., 2001. Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation. Cytokine 16, 106-119. (Pubitemid 34081705)
20. Li, X.Q., Lei, J.D., Su, Z.G., Ma, G.H., 2007. Comparison of bioactivities of monopegylated rhG-CSF with branched and linear mPEG. Process Biochem. 42, 1625-1631.
21. Monfardini, C., Schiavon, O., Caliceti, P., Morpurgo, M., Harris, J.M., Veronese, F.M., 1995. A branched monomethoxypoly (ethylene glycol) for protein modification. Bioconjugate Chem. 6, 62-69.
22. Nembrini, C., Marsland, B.J., Kopf, M., 2009. IL-17-producing T cells in lung immunity and inflammation. J. Allergy Clin. Immunol. 123, 986-994.
23. Nucci, M.L., Shorr, R., Abuchowski, A., 1991. The therapeutic value of poly (ethylene glycol)-modified proteins. Adv. Drug Deliv. Rev. 6, 133-151.
24. Oh, P., Li, Y., Yu, J., Durr, E., Krasinska, K.M., Carver, L.A., Testa, J.E., Schnitzer, J.E., 2004. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429, 629-635. (Pubitemid 38812308)
25. Park, J.B., Kwon, Y.M., Lee, T.Y., Brim, R., Ko, M.C., Sunahara, R.K., Woods, J.H., Yang, V.C., 2010. PEGylation of bacterial cocaine esterase for protection against protease digestion and immunogenicity. J. Control. Release 142, 174-179.
26. Pasut, G., Guiotto, A., Veronese, F.M., 2004. Protein, peptide and non-peptide drug PEGylation for therapeutic application. Expert Opin. Ther. Patents 14, 859-894.
27. Roitt, I., Bristoff, J., Male, D., 1985. Immunology. Gower Medical Publishing, London.
28. Roopenian, D.C., Akilesh, S., 2007. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715-725. (Pubitemid 47327396)
29. Stijlemans, B., Conrath, K., Cortez-Retamozo, V., Van Xong, H., Wyns, L., Senter, P., Revets, H., De Baetselier, P., Muyldermans, S., Magez, S., 2004. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. J. Biol. Chem. 279, 1256-1261. (Pubitemid 38082649)
30. Uyttenhove, C., Van Snick, J., 2006. Development of an anti IL 17A auto vaccine that prevents experimental auto immune encephalomyelitis. Eur. J. Immunol. 36, 2868-2874. (Pubitemid 44782560)
31. Van Snick, J., Cayphas, S., Vink, A., Uyttenhove, C., Coulie, P.G., Rubira, M.R., Simpson, R.J., 1986. Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc. Natl. Acad. Sci. U. S. A. 83, 9679-9683. (Pubitemid 17223420)
32. Veronese, F.M., 2009. PEGylated Protein Drugs: Basic Science and Clinical Applications. Birkhauser, Basel, Switzerland.
33. Veronese, F.M., Pasut, G., 2005. PEGylation, successful approach to drug delivery. Drug Discov. Today 10, 1451-1458. (Pubitemid 41483874)
34. Watson, E., Shah, B., DePrince, R., Hendren, R.W., Nelson, R., 1994. Matrix-assisted laser desorption mass spectrometric analysis of a pegylated recombinant protein. Biotechniques 16, 278-281. (Pubitemid 24056160)
35. Weir, A., Nesbitt, A., Chapman, A., Popplewell, A., Antoniw, P., Lawson, A., 2002. Formatting antibody fragments to mediate specific therapeutic functions. Biochem. Soc. Trans. 30, 512-516. (Pubitemid 35001587)
36. Weisser, N.E., Hall, J.C., 2009. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol. Adv. 27, 502-520.